Experience

ImCheck Therapeutics

• France
• Biotechnology
• 1 - 100 Employee

• Associate Director, program management

  • Nov 2022 - Present

  Marseille, Provence-Alpes-Côte d'Azur, France



ENYO Pharma

• France
• Biotechnology Research
• 1 - 100 Employee

• Program Manager

  • Mar 2018 - Nov 2022

  Lyon Area, France Transitioning an early phase project. Using my overall knowledge of pharmaceutical development to line up all the ducks for IND enabling studies, CMC and clinical. Great challenge!

• Clinical Trial Coordinator

  • Nov 2016 - Mar 2018

  Lyon Area, France



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Research Scientist I

  • Mar 2016 - May 2016

  - Lead pharmacologist for 3 of BMS’s oncology and immuno-oncology program; schedule, supervise and perform studies. - Managed the scientific alliance between BMS Oncology and one of its CRO overseas for 3 years. - Support clinical development using in-vivo and in-vitro assays following strict SOPs. - Collaborated with BMS’s Biomarker team using PDX models to predict potential patients’ selection. - Contribute as an active member of the Electronic notebook developer community… Show more - Lead pharmacologist for 3 of BMS’s oncology and immuno-oncology program; schedule, supervise and perform studies. - Managed the scientific alliance between BMS Oncology and one of its CRO overseas for 3 years. - Support clinical development using in-vivo and in-vitro assays following strict SOPs. - Collaborated with BMS’s Biomarker team using PDX models to predict potential patients’ selection. - Contribute as an active member of the Electronic notebook developer community - Lead the technological enhancement of the in vivo pharmacology group.

• associate research scientist II

  • Sep 2012 - Mar 2016

  Pre-clinical research in oncology and immuno-oncology also provide support data to clinical investigation using in-vivo and in-vitro techniques: - work with standard xenographs models and early passage Patient-Derived Xenograph (PDX) to evaluate small-molecule leads through extensive safety and anti-tumor efficacy testing. - evaluate drug mechanism of action with molecular biology tools. - deliver shRNA and siRNA in vivo to study the impact of individual gene on tumor… Show more Pre-clinical research in oncology and immuno-oncology also provide support data to clinical investigation using in-vivo and in-vitro techniques: - work with standard xenographs models and early passage Patient-Derived Xenograph (PDX) to evaluate small-molecule leads through extensive safety and anti-tumor efficacy testing. - evaluate drug mechanism of action with molecular biology tools. - deliver shRNA and siRNA in vivo to study the impact of individual gene on tumor progression. - assist in building cases for or against new oncology targets for early discovery using scientific publications, proprietary data, publicly available databases.

• associate research scientist I

  • Jan 2011 - Sep 2012

  Pre-clinical research in oncology and immuno-oncology: Profile promising oncology leads through extensive safety and efficacy testing.



Drexel University College of Medicine

• United States
• Higher Education
• 700 & Above Employee

• Research assistant II laboratory manager

  • Oct 2007 - Mar 2011

  - Coordinated our research with our collaborators Dr. Ari Brooks and Mauricio Reginato, Ph.D. - Coordinated rotation students’ work on the breast cancer project in order to obtain fast and reliable results. - Generated, within a year, a complete expression profile of serotonin receptors for the six most common breast cancer cell lines. - Kept the monthly expenses under an allocated fluctuating budget. - Worked in Drexel’s AALAC certified barrier facility. - Proficient with iv… Show more - Coordinated our research with our collaborators Dr. Ari Brooks and Mauricio Reginato, Ph.D. - Coordinated rotation students’ work on the breast cancer project in order to obtain fast and reliable results. - Generated, within a year, a complete expression profile of serotonin receptors for the six most common breast cancer cell lines. - Kept the monthly expenses under an allocated fluctuating budget. - Worked in Drexel’s AALAC certified barrier facility. - Proficient with iv injections, euthanasia and dissections. Show less



Drexel University College of Medicine

• United States
• Higher Education
• 700 & Above Employee

• Intern

  • Feb 2007 - Aug 2007

  - Started the project “Involvement of Serotonin in Breast Cancer” thanks to a Department of Defense (DOD) Concept Award. - Oriented our research toward a novel yet promising strategy to treat breast cancer. - Created a reference database linking serotonin to breast cancer phenotypes. - Screened breast cancer cell lines for a wide range of serotonin receptors antagonists. - Used FDA approved serotonin inhibitors, to recommend the submission of a “proof of principle”.



RheoGene

• Biotechnology Research

• Intern

  • Jul 2005 - Sep 2005

  - Optimized Real Time PCR and western blot procedures to detect proteins expressed using the inducible RheoSwtichTM technology. - Identified commercially available antibodies to VP16 and Gal4 that could detect the expressed proteins in human cells after transient transfection and induction when cloned behind the inducible system RheoSwitchTM.



RheoGene

• Biotechnology Research

• Intern

  • Jul 2004 - Sep 2004

  - Optimized ligand/receptor binding efficiency in RheoGene inducible gene expression technologies: RheoSwithTM and RheoPlexTM. Several patents registered. - Created strategic single point mutations to optimize the binding and subsequent induction of the inducible system. - Optimized multiple pairs ligand/receptor co-transfected deliberately avoiding cross-inductions for the RheoPlexTM system.